Provenienza dei contatti di primo grado di Richard Schoenfeld
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
PharmAthene, Inc. /Old/
 PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
14
| Extinct | Biotechnology | 14 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Richard Schoenfeld tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| SPECTRUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| GENVEC INC | Pharmaceuticals: Major | President | |
| DELCATH SYSTEMS, INC. | Medical Specialties | Director/Board Member | |
| JPMORGAN CHASE & CO. | Major Banks | Corporate Officer/Principal | |
| ACHILLION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| RADIUS HEALTH, INC. | Biotechnology | Director/Board Member Director/Board Member | |
OMRIX Biopharmaceuticals, Inc.
 OMRIX Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| TETRALOGIC PHARMACEUTICALS CORPORATION | Pharmaceuticals: Major | Founder | |
SCILEX Pharmaceuticals, Inc.
 SCILEX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA. | Pharmaceuticals: Major | Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Graduate Degree Undergraduate Degree | |
| AFFYMAX, INC. | Biotechnology | Director/Board Member | |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Biotechnology | Corporate Officer/Principal | |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal | |
Agensys, Inc.
 Agensys, Inc. Miscellaneous Commercial ServicesCommercial Services Agensys, Inc. develops a pipeline of therapeutic fully human monoclonal atibodies (mAbs) to treat cancer. It develops a pipeline of naked and antibody-drug conjugated (ADC) therapeutic antibodies to treat cancer indications, including prostate, kidney, pancreas, ovary, bladder, lung, colon, breast, and skin. The company was founded in 1997 and is headquartered in Santa Monica, CA. | Miscellaneous Commercial Services | Director/Board Member | |
BASF Pharma Ltd.
 BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Pharmaceuticals: Major | Director/Board Member | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Masters Business Admin | |
| Marshall University | College/University | Undergraduate Degree | |
| University of Maryland | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of South Florida | College/University | Undergraduate Degree Graduate Degree | |
Ben Franklin Technology Partners /Ventures/
 Ben Franklin Technology Partners /Ventures/ Investment ManagersFinance Ben Franklin Technology Partners /Ventures/ (Ben Franklin Tech Partners) is a venture Capital firm founded in 1982. The firm is headquartered in Philadelphia, Pennsylvania. | Investment Managers | Director/Board Member | |
National Venture Capital Association
 National Venture Capital Association Miscellaneous Commercial ServicesCommercial Services National Venture Capital Association provides business association services. It facilitates networking opportunities and provides research data to its members. The company is headquartered in Washington, DC. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
| Licensing Executives Society | Corporate Officer/Principal | ||
| Knoll Pharmaceutical Co. | Director/Board Member | ||
| Cwd Enterprises, Inc. | President | ||
| BIOptima Advisors LLC | Founder | ||
UBS Oncology Impact Fund
 UBS Oncology Impact Fund Investment ManagersFinance UBS Oncology Impact Fund is an American private company located in Cambridge, MA, with a presence in the Cayman Islands, that functions as a family of funds. | Investment Managers | Director/Board Member | |
| ALTIMMUNE, INC. | Biotechnology | Director/Board Member Director/Board Member Director of Finance/CFO | |
| MPM Sunstates GP Managing Member LLC | Corporate Officer/Principal | ||
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million. | Biotechnology | Director/Board Member | |
| Isarna Therapeutics, Inc. | Director of Finance/CFO | ||
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on September 30, 2008 and is headquartered in Toronto, Canada. | Biotechnology | Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder |
Statistiche
Distribuzione geografica
| Stati Uniti | 48 |
| Regno Unito | 2 |
| Francia | 2 |
| Canada | 2 |
Settori
| Health Technology | 24 |
| Finance | 9 |
| Consumer Services | 6 |
| Commercial Services | 5 |
| Health Services | 4 |
Posizioni
| Director/Board Member | 132 |
| Corporate Officer/Principal | 47 |
| Founder | 21 |
| President | 21 |
| Independent Dir/Board Member | 20 |
Contatti più connessi
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| James Cavanaugh | 38 |
| Derace L. Schaffer | 37 |
| Elizabeth Czerepak | 32 |
| Steven St. Peter | 26 |
| Mack Gill | 21 |
| Joel W. McCleary | 12 |
| Solomon Langermann | 10 |
| David P. Wright | 9 |
| Valerie D. Riddle | 8 |
| Christopher C. Camut | 8 |
| Wayne Morges | 6 |
| Francesca M. Cook | 5 |
| John Mekalanos | 1 |
- Borsa valori
- Insiders
- Richard Schoenfeld
- Connessioni Società
